Does a Mother's pregnancy health shape her Child's future heart?
NCT ID NCT05223530
First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time
Summary
Researchers are following up with mothers who took part in two pregnancy studies and their children, who are now 11 to 17 years old. The goal is to see whether maternal obesity, high blood pressure during pregnancy, gestational diabetes, and substances measured in the blood during pregnancy are linked to children's weight, body fat, blood pressure, and heart health. Families attend a study visit where researchers measure body composition, blood pressure, and blood vessel stiffness. The study does not test a treatment; it looks for patterns that might explain how early life influences later health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the study finds links between pregnancy factors and later heart or weight problems, it could shape future pregnancy care and early screening for children at higher risk.
- What could go wrong
- This is an observational follow-up, so it can show associations but not prove cause and effect. Many other factors over 11 to 17 years could influence the children's health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population comprises two Finnish pregnancy cohort /prevention studies, in which mother-child pairs have already been followed from early pregnancy until the threshold of adolescence. Women for the PREDO study were enrolled at 12-14 gestational weeks and for the RADIEL study before conception or at 10-12 gestational weeks. They gave birth to a singleton live infant between 2006-2010 (PREDO) and 2008-2014 (RADIEL).
- Ages
-
11 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * all mothers participated originally in the PREDO or the RADIEL studies during pregnancy and with delivery during this index pregnancy Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiometabolic diseases are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Saila Koivusalo
RECRUITINGHelsinki, 00290, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injectables put to the test in obesity
- Once-a-Month obesity shot put to the test
- Can GPS tech help surgeons align knee implants in obese patients?
- A new pill aims at weight and blood sugar
- New semaglutide injection tested against wegovy for obesity
- New obesity drug VK2735 put to the test in early human trial